Adhera Therapeutics, Inc. (ATRX) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.73: the stock has moved about 273% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAdhera Therapeutics, Inc. (ATRX) trades at $0.0001. Adhera Therapeutics, Inc. is a biotechnology company focused on the discovery and development of drugs. Formerly known as Marina Biotech, the company is based in Baton Rouge, Louisiana. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ATRX: ATRX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATRX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ATRX: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Adhera Therapeutics, Inc. (ATRX) Healthcare & Pipeline Overview
Adhera Therapeutics, Inc., formerly Marina Biotech, focuses on drug discovery and development within the biotechnology sector. Based in Baton Rouge, Louisiana, the company operates with a small team, navigating the competitive landscape of pharmaceutical innovation with a focus on identifying and advancing novel therapeutic candidates.
What Is the Investment Thesis for ATRX?
Investing in Adhera Therapeutics presents a high-risk, high-reward scenario typical of early-stage biotechnology companies. With a market capitalization of $0.00 billion and a negative price-to-earnings ratio, the company's valuation is speculative and tied to the potential success of its drug development pipeline. A key value driver is the advancement of drug candidates through clinical trials, which could trigger significant stock appreciation. Upcoming catalysts include potential partnerships, grant funding, and positive clinical trial results. However, the company faces substantial risks, including limited financial resources, regulatory hurdles, and competition from larger pharmaceutical companies. The high beta of 3.73 indicates significant volatility, making this investment suitable only for risk-tolerant investors.
Based on FMP financials and quantitative analysis
ATRX Key Highlights
Market capitalization of $0.00 billion, reflecting its status as a micro-cap company.
- Negative price-to-earnings ratio, indicating the company is currently not profitable.
- Beta of 3.73, suggesting high volatility compared to the overall market.
- Focus on drug discovery and development, positioning it within the high-growth biotechnology sector.
- Operates with a small team of 2 employees, indicating a lean operational structure.
Who Are ATRX's Competitors?
ATRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.96 | -0.06% | $624M | 885-pillar |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are ATRX's Key Strengths?
Focus on drug discovery and development
- Small, agile team
- Potential for breakthrough therapies
- Strategic location in Baton Rouge, Louisiana
What Are ATRX's Weaknesses?
Limited financial resources
- Small team size
- Dependence on external funding
- Lack of commercialized products
What Could Drive ATRX Stock Higher?
Potential partnerships with larger pharmaceutical companies to fund and develop drug candidates.
- Grant funding from government agencies or non-profit organizations to support research and development.
- Positive results from preclinical studies of drug candidates.
- Advancement of drug candidates through clinical trials.
- Expansion into new therapeutic areas to diversify the pipeline.
What Are the Key Risks for ATRX?
Inconsistent delivery — missed Wall Street EPS estimates in 8 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Limited financial resources to fund drug development programs.
- Competition from larger, better-funded pharmaceutical companies.
- Regulatory hurdles and approval delays for drug candidates.
- Clinical trial failures and setbacks.
- Dependence on external funding and strategic partnerships.
What Are the Growth Opportunities for ATRX?
- Expansion into New Therapeutic Areas: Adhera Therapeutics can explore new therapeutic areas beyond its current focus to diversify its pipeline and reduce risk. The global market for pharmaceuticals is projected to reach $1.5 trillion by 2026. Entering new areas like oncology or immunology could open up significant revenue streams. This expansion would require strategic partnerships and additional funding, with potential impact visible within 3-5 years.
- Strategic Partnerships and Collaborations: Forming partnerships with larger pharmaceutical companies or research institutions can provide Adhera Therapeutics with access to funding, expertise, and resources. The value of biotech collaborations reached $150 billion in 2025. A successful partnership could accelerate drug development and increase the company's visibility. Expect potential partnership announcements within the next 1-2 years.
- Securing Grant Funding: Pursuing grant funding from government agencies and non-profit organizations can provide non-dilutive capital to support research and development efforts. The National Institutes of Health (NIH) awards billions of dollars in grants annually. Securing even a small grant could significantly extend the company's runway. Grant applications and approvals typically take 6-12 months.
- Advancement of Drug Candidates Through Clinical Trials: Successfully advancing drug candidates through clinical trials is critical for creating value. Positive clinical trial results can lead to regulatory approval and commercialization. The cost of bringing a drug to market can exceed $2 billion. Each phase of clinical trials represents a major milestone and potential catalyst for the stock. Expect incremental progress updates on clinical trials every 6-18 months.
- Acquisition by a Larger Pharmaceutical Company: Given its focus on drug discovery, Adhera Therapeutics could become an acquisition target for a larger pharmaceutical company seeking to expand its pipeline. The value of biotech acquisitions reached $200 billion in 2025. A successful acquisition would provide a significant return for investors. The likelihood of an acquisition depends on the progress of its drug candidates and the overall market environment. Timing is unpredictable, but potential within 2-5 years.
What Are ATRX's Competitive Advantages?
- Proprietary drug discovery platform.
- Intellectual property protection for its drug candidates.
- Expertise in specific therapeutic areas.
What Does ATRX Do?
Adhera Therapeutics, Inc., headquartered in Baton Rouge, Louisiana, is a biotechnology company engaged in the discovery and development of pharmaceutical products. Originally established as Marina Biotech, Inc., the company underwent a name change in October 2018 to reflect its evolving strategic direction. Adhera Therapeutics operates with a lean structure, currently managing its research and development efforts with a team of two employees. The company's primary focus is on identifying and developing novel drug candidates, aiming to address unmet medical needs. While specific details on their current pipeline are not available, the company's history suggests an interest in innovative therapeutic approaches. Adhera Therapeutics navigates the competitive biotechnology landscape, seeking to advance its drug development programs through preclinical and clinical stages.
What Products and Services Does ATRX Offer?
- Focuses on the discovery of new drugs.
- Engages in the development of pharmaceutical products.
- Aims to address unmet medical needs through innovative therapies.
- Conducts preclinical research to identify promising drug candidates.
- Potentially conducts clinical trials to evaluate the safety and efficacy of drug candidates.
- Seeks partnerships and collaborations to advance its drug development programs.
How Does ATRX Make Money?
- Focuses on discovering and developing drugs.
- Seeks to monetize its drug candidates through partnerships or acquisitions.
- May generate revenue through licensing agreements or milestone payments.
What Industry Does ATRX Operate In?
Adhera Therapeutics operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital demands. The industry is driven by innovation, with companies constantly seeking to develop novel therapies for unmet medical needs. The competitive landscape includes established pharmaceutical giants, as well as numerous smaller biotechnology firms. Adhera Therapeutics, with its small size and focus on drug discovery, faces the challenge of competing with larger, better-funded companies. Success in this industry requires strong intellectual property, efficient clinical trial execution, and strategic partnerships.
Who Are ATRX's Key Customers?
- Pharmaceutical companies seeking to expand their drug pipelines.
- Patients who may benefit from new therapies developed by the company.
- Healthcare providers who may prescribe the company's drugs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 51 |
| 2026-08-29 | 51 |
| 2026-09-01 | 51 |
| 2026-09-04 | 51 |
| 2026-09-07 | 51 |
| 2026-09-10 | 51 |
What changed?
The score has stayed at 51.
Over the same 18 days the stock moved +0.0%.
Financial Health
Adhera Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Adhera Therapeutics, Inc. stands at 8.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Adhera Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Baton Rouge, US. The company is led by CEO David A. Battat. ATRX has traded publicly since 1993.
Earnings Track Record
Adhera Therapeutics, Inc. has missed Wall Street's EPS estimate in 8 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 188.7% below estimates on average.
Insider Activity
The most recent 5 insider filings for Adhera Therapeutics, Inc. break down as 1 sales and 4 purchases. On net that is roughly 1.8M shares acquired (about $534K) — insiders putting money in tends to read as conviction.
ATRX Financials
Bull Case vs Bear Case
Bull Case
- Focus on drug discovery and development
- Small, agile team
- Potential for breakthrough therapies
- Strategic location in Baton Rouge, Louisiana
Bear Case
- Limited financial resources
- Small team size
- Dependence on external funding
- Lack of commercialized products
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ATRX Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Nov 15, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Sep 12, 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· Aug 21, 2019
ATRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ATRX.
Price Targets
Wall Street price target analysis for ATRX.
ATRX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ATRX; grades run from A+ (80-100) to F (below 30).
Leadership: Andrew Albert Kucharchuk
CEO
Andrew Albert Kucharchuk serves as the CEO of Adhera Therapeutics, Inc. As the managing member of a small team, Kucharchuk is responsible for overseeing the company's strategic direction and day-to-day operations. His leadership is critical to navigating the challenges of drug discovery and development within the biotechnology sector.
Track Record: Given the limited information available, it is difficult to assess Andrew Albert Kucharchuk's track record at Adhera Therapeutics. The company's small size and early stage of development suggest that Kucharchuk's primary focus has been on securing funding, advancing drug candidates, and building strategic partnerships. Key milestones under his leadership would include successful preclinical studies, IND filings, and positive clinical trial results.
ATRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Adhera Therapeutics may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and regulatory oversight. This contrasts sharply with companies listed on major exchanges like the NYSE or NASDAQ, which have stringent listing requirements and reporting obligations.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements (if available)
- Research the background of the company's management team
- Assess the company's business model and competitive landscape
- Review any available news articles or press releases
- Consult with a financial advisor
- Understand the risks associated with investing in OTC stocks
- Confirm the company's registration status with the SEC (if applicable)
- Company's history of operations (formerly Marina Biotech)
- Focus on drug discovery and development
- Presence of a CEO and management team
- Company filings with OTC Markets (if available)
- Any patents or intellectual property owned by the company
What Investors Ask About Adhera Therapeutics, Inc. (ATRX) — Healthcare
Is ATRX a good stock?
Stock Expert AI does not rate ATRX buy, sell or hold. Adhera Therapeutics, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about ATRX stock?
As of 2026-03-17, there is no available analyst coverage for Adhera Therapeutics (ATRX). Given its micro-cap status, OTC listing, and limited financial disclosure, the stock is not widely followed by analysts.
What are the key factors to evaluate for ATRX?
Evaluate ATRX on fundamentals, analyst consensus, and risk factors. A key value driver is the advancement of drug candidates through clinical trials, which could trigger significant stock appreciation. Not financial advice.
How frequently does ATRX data refresh on this page?
ATRX's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ATRX's recent stock price performance?
Adhera Therapeutics, Inc. (ATRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on drug discovery and development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATRX overvalued or undervalued right now?
Adhera Therapeutics, Inc. (ATRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ATRX?
Yes, most major brokerages offer fractional shares of Adhera Therapeutics, Inc. (ATRX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ATRX's earnings and financial reports?
Adhera Therapeutics, Inc. (ATRX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ATRX earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's current pipeline and financial performance.
- OTC listing indicates higher risk and lower transparency.